The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment
Laura N Eadie(South Australian Health and Medical Research Institute), Deborah L. White(ANZCHOG), V. A. Saunders(South Australian Health and Medical Research Institute), P Dang(South Australian Health and Medical Research Institute), Timothy P. Hughes(Royal Adelaide Hospital), Michael Osborn, Andrew Grigg(The Royal Melbourne Hospital), David T Yeung(Royal Adelaide Hospital)
Cited by 68
Related Papers
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
|Journal of Clinical Oncology|2016|867
Comprehensive Analysis of Hypermutation in Human Cancer
|Cell|2017|795
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464